Animace načítání

Stránka se připravuje...


Na co čekáte? Nečekejte už ani minutu.
Získejte přístup na tento text ještě dnes. Kontaktujte nás a my Vám obratem uděláme nabídku pro Vás přímo na míru.

Právní předpis byl sestaven k datu 20.04.2026.

Zobrazené znění právního předpisu je účinné od 28.01.2025.


Sdělení Ministerstva zahraničních věcí, kterým se mění a doplňují sdělení Ministerstva zahraničních věcí č. 58/2007 Sb. m. s. a č. 46/2008 Sb. m. s.

19/2025 Sb.
 

Sdělení

INFORMACE

19

XXXXXXX

Xxxxxxxxxxxx zahraničních věcí,

kterým xx xxxx a xxxxxxxx sdělení Xxxxxxxxxxxx xxxxxxxxxxxx xxxx č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.
&xxxx;

Xxxxxxxxxxxx xxxxxxxxxxxx xxxx sděluje, xx xxx 1. xxxxx 2023 xxxx xxxxxxxxx xxxxxxxxxx XXXXXX xxxxxxxx xxxxxxxxx xxxxxx xxxxx Xxxxxxx I - Xxxxxx xxxxxxxxxx xxxxx x metod xxxxxxx xxx rok 2024 - Mezinárodní xxxxxxxx Xxxxxxxxxxx úmluvy xxxxx xxxxxxx ve xxxxxx.

X xxxxx zněním Xxxxxxx X vyslovil xxxxxxx Xxxxxxxxx Xxxxx republiky x prezident republiky xxxxxxxx xxxxxxx x xxxxxxx xxxx Přílohy X Xxxxxx republikou.

Nové xxxxx Xxxxxxx X xxxxxxxxx x xxxxxxxx x xxxxxxx x článkem 34 odst. 3 Xxxxxx dne 1. xxxxx 2024, xxx Xxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxxx xxx 18. xxxxxx 2024 x nahradilo Xxxxxxx X xxx xxx 2023, platnou od 1. ledna 2023, xxxxx xxxxxxxxx v xxxxxxxx xxx Českou xxxxxxxxx xxx 22. xxxxxx 2023 x xxxx xxxxxxxxx xxx č. 32/2023 Sb. m. s.

Xxxxxxxx xxxxx Xxxxxxx X xxx xxx 2024 a xxxx xxxxxxx xx xxxxxxx xxxxxx xx xxxxxxxxx xxxxxxxx.
&xxxx;

Xxxxxxx:

x x. XXXx. Xxxxxx, Ph.D., XX.X., x. x.

xxxxxx xxxxxxx xxxxx xxxxxx x xxxxxxxxxx
&xxxx;

Xxxxxxx x. 1

Překlad xxxxxxxxxxx xxxxxxx do xxxxxxx xxxxxx

Xxxx

Xxxxxx xxxxxxxxxx xxxxx a xxxxx xxxxxxx je xxxxxxx Xxxxxxxxxxx standard x xxxxx Světového xxxxxxxxxxxxxxx xxxxxxxx.

Xxxxxx xx xxxxxxxxxx xxxxxxxxxxxx xx rozsáhlém xxxxxxxxxxxx xxxxxxx zprostředkovaném Xxxxxxxx antidopingovou xxxxxxxxx (XXXX). Seznam je xxxxxx xx 1. xxxxx 2024.

Xxxxxxxxx text Xxxxxxx xxxxxxxxxx xxxxx x xxxxx xxxx xxxxxxxxx XXXX x xxxx publikován v xxxxxxxxxx a xxxxxxxxxxxxx. X xxxxxxx xxxxxxxxxxx xxxxxxxxxxxxx mezi xxxxxxxxx x xxxxxxxxxxxx textem xxxxxxxxx xxxxx x xxxxxxxxxx.

Xxxx jsou uvedeny xxxxxxx xxxxx používané x xxxxx Xxxxxxx xxxxxxxxxx xxxxx x xxxxx.

Xxxxxxxx Při xxxxxxx

Xxxxx XXXX xxx xxxx xxxxx xxxxxxxxxxx xxxx xxxxxx, xx xxxxxx Xxx xxxxxxx x xxxxxx xxxxxxx začínajícím xxxxx xxxx xxxxxxx (xx 23:59 hodin) x xxx předcházející Xxxxxxx, xxxxx xx xx Sportovec zúčastnit, xx xx xxxxx Xxxxxxx x xxxxxxx xxxxxx Vzorku.

Zakázané xxxxx

Xx xxxxxxx, xx xxxx xxxxx xxxx xxxxxx xx xxxxxxxx Při xxxxxxx x Mimo xxxxxx, xxx xx xxxxxxxxxx x Xxxxxx.

Xxxxxxxxxx x Xxxxxxxxxxxx

Xxxxx xxxxxx 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx Xxxxxx „xxx účely xxxxxxxx xxxxxx 10 xxxxx xxxxxxx Xxxxxxxx xxxxx Xxxxxxxxxxxx xxxxxxx, x výjimkou těch xxxxxxxxxx v Seznamu xxxxxxxxxx látek a xxxxx xxxxxxx. Žádná Xxxxxxxx xxxxxx xxxxxx Xxxxxxxxxxx xxxxxxx, pokud xxxx x Xxxxxxx xxxxxxxxx xxxxxxxx jako Xxxxxxxxxx xxxxxx.“ Xxxxx xxxxxxxxx x článku „Xxxxxxxxxx xxxxx x Xxxxxxxxxx metody xxxxxxx x xxxxxx 4.2.2 xx xxxxxx být xxxxxx xxxxxxxx xxxxxxxxxx xx xxxx xxxxxxxx xxxx méně xxxxxxxxxx xxx xxxx xxxxxxxxx xxxxx xxxx metody. Xxx spíše x xxxxx x xxxxxx, xxxxx Sportovec xxxxxxxxxxxxx xxxx xxxx xxxxxx x xxxxxx účelu xxx ke xxxxxxxx xxxxxxxxxxx xxxxxx.“

Xxxxxxxx xxxxx

Xxxxx xxxxxx 4.2.3 Xxxxxx xxxx Xxxxxxxx látky xxxxxxxxxx xxxx xxxxx, xxxxx jsou jako xxxxxx xxxxxxxx x xxxxxx jejich xxxxxxx xxxxxxxxxx xx xxxxxxxxxxx xxxx xxxxx xxxxxx. Xxxx Návykové látky xxxx xxxxxxxxxx xxxx xxxxx: xxxxxx, xxxxxxxxx (xxxxxx), methylendioxymetamfetamin (XXXX/„xxxxxx“), xxxxxxxxxxxxxxxxxxx (XXX).

X0 NESCHVÁLENÉ XXXXX

XXXXXXXX XXXXX (XXX XXXXXXX I XXXX XXXXXX)

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.

Xxxxxxxxx xxxxxxxxxxxxxx látka, na xxxxxx se xxxxxxxxxx xxxxx z xxxxxxxxxxxxx xxxxxx Seznamu x xxxxx xxxx x xxxxxxxx xxxx xxxxxxxxx xxxxxx xxxxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxxx xxx xxxxxxx xxxxxxx u xxxx (např. léčiva x xxxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx xxxx xxxxxxx vývoj xxx xxxxxxx, syntetické xxxxx, xxxxx xxxxxxxxx pouze xxx xxxxxxxxxxx xxxxxxx), xx xxxxxxxx xxxxx.

Xxxx xxxxx zahrnuje mnoho xxxxxxx látek, xxxx xxxx XXX-157, 2,4-xxxxxxxxxxxx (XXX) x aktivátory xxxxxxxxx (např. Reldesemtiv x Xxxxxxxxxx).

X1 XXXXXXXXXX XXXXX

XXXXXXXX STÁLE (XXX XXXXXXX X XXXX XXXXXX)

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxxxx látky.

Anabolické xxxxx xxxx zakázány.

S1.1. XXXXXXXXXX ANDROGENNÍ XXXXXXXX (XXX)

Xxx xxxxxxxxx podání, xxxx xxxx včetně:

1-androstenediol (5ɑ-xxxxxxx-1-xx-3ß, 17ß-xxxx)

&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;

&xxxx;•&xxxx;

xxxxxxxxxx

1-xxxxxxxxxxxxxx (5ɑ-xxxxxxx-1-xx-3,17-xxxx)

&xxxx;•

xxxxxxxxx (17ɑ-xxxxxx [1,2,5]oxadiazolo[3’,4’:2,3]-5ɑ-androstan-17ß-ol)

1-androsteron (3ɑ-xxxxxxx-5x-xxxxxxx-1-xx-17-xx)

&xxxx;•

xxxxxxxxx

1-xxxxxxxxxxxxxx (3ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-17-xx)

&xxxx;•

xxxxxxxxxx

1-xxxxxxxxxxx (17ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-3-xx)

&xxxx;•

xxxxxxxxxx

4-xxxxxxxxxxxxxx (xxxxxxx-4-xx-3ß, 17ß-xxxx)

&xxxx;•

xxxxxxxxxxx (17ß-hydroxy-17ɑ-methylandrosta-1,4-dien-3-on)

4-hydroxytestosteron(4,17ß-dihydroxyandrost-4-en-3-on)

 •

metenolon

5-androstenedion (androst-5-en-3,17-dion)

 •

metandriol

7ɑ-hydroxy-DHEA

 •

metasteron (17β-xxxxxxx-2α,17α-xxxxxxx-5α-xxxxxxxxx-3-xx)

7ß-xxxxxxx-XXXX

&xxxx;•

xxxxx-1-xxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxx-5ɑ-xxxxxxx-1-xx-3-xx)

7-xxxx-XXXX

&xxxx;•

xxxxxxxxxxxxxx

11ß-xxxxx-19-xxxxxxxxxxxxxx

&xxxx;•

xxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4,9-xxxx-3-xx)

17ɑ-xxxxxxxxxxxxxxxxxxx (xxxxxxx)

&xxxx;•

xxxxxxxxxxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxxxxxx-4-xx-3-xx)

19-xxxxxxxxxxxxxxxxx (estr-4-en-3,17-diol)

 •

metyltestosteron

19-norandrostenedion (xxxx-4-xx-3,17-xxxx)

&xxxx;•

xxxxxxxxxx (xxxxxxxxxxxxxx, 17ß-xxxxxxx-17ɑ-xxxxxxxxxxx-4,9,11-xxxxx-3-xx)

Xxxxxxx-4-xx-3,11,17-xxxxx(11-xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxx)

&xxxx;•

xxxxxxxxx

xxxxxxxxxxxxx (5ɑ-xxxxxxxxxxxxxxxxxx, 17ß-xxxxxxx-5ɑ-xxxxxxxxx-3-xx)

&xxxx;•

xxxxxxxxx (19-xxxxxxxxxxxxxx)

xxxxxxxxxxxxxx (androst-5-en-3ß,17ß-diol)

 •

norboleton

androstenedion (xxxxxxx-4-xx-3,17-xxxx)

&xxxx;•

xxxxxxxxxxxx (4-xxxxxx-17β-xx-xxxx-4-xx-3-xx)

xxxxxxxxxx

&xxxx;•

xxxxxxxxxxxxx

xxxxxxxx

&xxxx;•

xxxxxxxx

xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx)

&xxxx;•

xxxxxxxxxx

xxxxxxxxxx

&xxxx;•

xxxxxxxxxxx

xxxxxxxxx

&xxxx;•

xxxxxxxxxx

xxxxxxx ([1,2]xxxxxxx[4’,5’:2,3]xxxxxx-4-xx- 20-xx-17ɑ-xx)

&xxxx;•

xxxxxxxxx (dehydroepiandrosteron, DHEA, 3β-xxxxxxxxxxxxxx-5-xx-17-xx)

xxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx- 17ß-hydroxy-17ɑ-metylandrosta-1,4-dien-3-on)

 •

prostanozol (17β-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxx)

xxxxxxxxxxxxxxxxxxxxxx (17ɑ-methyl-5ɑ-androst-2-en-17ß-ol x 17ɑ-xxxxx-5ɑ- androst-3-en-17ß- xx)

&xxxx;•

xxxxxxxxx

xxxxxxxxxxxxx (7ɑ,11ß-xxxxxxx-19-xxxxxxxxxxxxxx)

&xxxx;•

xxxxxxxxxx

xxxxxxxxxxx

&xxxx;•

xxxxxxxxx

xxxxxxxxxxxxxx (3β-xxxxxxx-5α-xxxxxxxxx-17-xx)

&xxxx;•

xxxxxxxxxxx

xxx-xxxxxxxxxxxxxxxxxx (17β-xxxxxxx-5β-xxxxxxxxx-3-xx)

&xxxx;•

xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18x-xxxx-19-xxx-17ɑ-xxxxxx-4,9,11-xxxxx-3-xx)

xxxxxxxxxxxxxx

&xxxx;•

xxxxxxx

xxxxxxxxxxxx (19-xxxxxxxxx-4-xx-17α-xx)

&xxxx;•

xxxxxxxxx (17β-hydroxyestr-4,9,11-trien-3-on)

fluoxymesteron

 •

trestolon (7ɑ-xxxxx-19-xxxxxxxxxxxxxx, XXXX)

x xxxxx xxxxx s podobnou xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx účinky.

S1.2. XXXXXXX XXXXXXXXXX LÁTKY

Mimo xxxx xxxxxx:

Xxxxxxxxxxx, osilodrostat, xxxxxxxxxx, xxxxxxxxxx modulátory xxxxxxxxxxxxx xxxxxxxxx [SARM, xxxx. xxxxxxx, enobosarm (xxxxxxx), XXX-4033 (xxxxxxxxx), XXX140, X-23 a XX-11], xxxxxxx x xxxxxxxxxx.

X2 PEPTIDOVÉ XXXXXXX, XXXXXXX XXXXXXX, PŘÍBUZNÉ XXXXX X XXXXXXXX

XXXXXXXX XXXXX (XXX SOUTĚŽI X MIMO SOUTĚŽ)

Všechny xxxxxxxx látky x xxxx xxxxx xxxx Xxxxxxxxxxxx látky.

Následující látky x xxxxx xxxxx x xxxxxxxx chemickou xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx xxxxxx jsou xxxxxxxx.

X2.1. ERYTROPOETINY (XXX) X LÁTKY XXXXXXXXXXX XXXXXXXXXXX

Xxxx jiné xxxxxx:

X2.1.1 Xxxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxx, xxxx. xxxxxxxxxxxx (xXXX); xxxxxxxxxxxxx (XXX); sloučeniny xxxxxxxx xx EPO, [xxxx. XXX-Xx, xxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX)]; EPO- xxxxxxxxx xxxxxxxxxx x xxxxxx sloučeniny, např. XXXX-530, peginesatid.

S2.1.2 Xxxxxxxxx xxxxxxxxxx hypoxii xxxxxxxxxxxxxx xxxxxxx (XXX), xxxx. xxxxxx; xxxxxxxxxxx (XXX1278863); XXX2; molidustat (XXX 85-3934); xxxxxxxxxx (XX-4592); xxxxxxxxxx (XXX-6548); xenon.

S2.1.3 Xxxxxxxxxx XXXX, např. X-11706.

X2.1.4 Xxxxxxxxxx signalizace xxxxxxxxxxxxxxxx růstového faktoru xxxx (XXX-β), např. xxxxxxxxxxxx; xxxxxxxxxxx.

X2.1.5 Xxxxxxxx xxxxxxxxx opravného receptoru, xxxx. xxxxxx EPO; xxxxxxxxxxxxx EPO (CEPO).

S2.2. XXXXXXXXX HORMONY X XXXXXX XXXXXXXXXX FAKTORY

S2.2.1 Xxxxxxx xxxxxxxxxxx xxxxxxxxxxx x xxxx, xxxx xxxx včetně:

• xxxxxxxx xxxxxxxxxxxx (CG),

• luteinizační xxxxxx (XX),

• xxxxxx xxxxxxxxxx xxxxxxxxxxxx (XxXX, xxxxxxxxxxx) x xxxx xxxxxxxxxxx xxxxxxx (xxxx. xxxxxxxxx, deslorelin, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx x xxxxxxxxxxx),

&xxxx;• kisspeptin x xxxx xxxxxxxxxxx xxxxxxx.

X2.2.2 Kortikotropiny x xxxxxx uvolňující faktory, xxxx. kortikorelin x xxxxxxxxxxxxx.

X2.2.3 Xxxxxxx xxxxxx (XX), xxxx xxxxxxx x xxxxxxxxx, xxxx xxxx xxxxxx:

• analogy xxxxxxxxx xxxxxxx, např. xxxxxxxxxxxxxxxxx, somapacitan x xxxxxxxxxx,

• xxxxxxxxx růstového xxxxxxx, xxxx. XXX-9604 x hGH 176–191.

X2.2.4 Xxxxxxx xxxxxxxxxx xxxxxxx xxxxxx, xxxx xxxx xxxxxx:

• hormon xxxxxxxxxx xxxxxxx xxxxxx (GHRH) x xxxx xxxxxxx, xxxx. CJC-1293, CJC-1295, xxxxxxxxxx a xxxxxxxxxxx,

• xxxxxxxxxxx xxxxxxxxx hormonu (XXX) x xxxxxx xxxxxxxx [xxxx. xxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx (XX-677), xxxxxxxxxx, xxxxxxxxxxx (xxxxxxx), xxxxxxxxxxx a xxxxxxxxxxx],

• xxxxxxx uvolňující XX (XXXX) [xxxx. alexamorelin, xxxxxxxxxx (xxxxxxxxx), XXXX-1, XXXX-2 (pralmorelin), XXXX-3, XXXX-4, XXXX-5 a XXXX-6].

X2.3. XXXXXXX XXXXXXX X MODULÁTORY XXXXXXXXX XXXXXXX

Xxxx xxxx xxxxxx:

• xxxxxxxxxxxxx xxxxxxx faktory (XXX)

• xxxxxxxxxxxx růstový xxxxxx (XXX)

• růstový xxxxxx 1 podobný xxxxxxxx (XXX-1, xxxxxxxxxx) x xxxx xxxxxxx

• xxxxxxxxxx xxxxxxx xxxxxxx (XXX)

• růstový xxxxxx xxxxxxxx z xxxxxxxx xxxxxxxx (XXXX)

• xxxxxxxx-β4 x xxxx xxxxxxxx, xxxx. XX-500

• vaskulárně-endoteliární xxxxxxx faktor (XXXX)

x xxxxx xxxxxxx xxxxxxx xxxx xxxxxxxxxx růstových xxxxxxx xxxxxxxxxxx syntézu/degradaci xxxxxxxx ve xxxxxxx, xxxxxxxx xxxx vazech, xxxxxxxxxxxxx, xxxxxxx energie, xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx xxxx svalových xxxxxx.

X3 XXXX-2 XXXXXXXX

XXXXXXXX XXXXX (PŘI XXXXXXX X XXXX SOUTĚŽ)

Všechny xxxxxxxx látky v xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.

Xxxxxxx xxxxxxxxxx x neselektivní xxxx-2 xxxxxxxx xxxxxx všech xxxxxxxxx izomerů jsou xxxxxxxx.

Xxxx jiné xxxxxx:

xxxxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxxx (xxxxxxxxxxxxx)

xxxxxxxxx

xxxxxxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxx

xxxxxxxxx

xxxxxxxxxx

xxxxxxxxxx

XXXXXXX

• Xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 1600 xxxxxxxxxx xx 24 xxxxx x oddělených xxxxxxx, xxxxxxxxxxxxxxxx 600 mikrogramů xxxxx 8 xxxxx xx xxxxxxxxx xxxxx;

• xxxxxxxxx formoterol: xxxxxxxxx xxxxxx xxxxx 54 xxxxxxxxxx za 24 xxxxx;

• inhalační salmeterol: xxxxxxxxx 200 mikrogramů xx 24 xxxxx;

• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 25 xxxxxxxxxx xx 24 xxxxx.

XXXXXXXX

Xxxxxxxxxx xxxxxxxxxxx x xxxx x xxxxxxxx xxxxxx xxx 1000 ng/ml xxxx xxxxxxxxxxx v xxxxxxxx xxxxxx xxx 40 xx/xx neodpovídá terapeutickému xxxxxxx látky x xxxx xxxxxxxxxx za Xxxxxxxxx xxxxxxxxxxx xxxxx (XXX), xxxxx Xxxxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxx, xx xxxxxxxxxx xxxxxxxx xxx důsledkem xxxxxxxxxxxx dávky (xxxxxxxxx) xx do výše xxxxxxx maximální xxxxx.

X4 XXXXXXXXX X XXXXXXXXXXX XXXXXXXXXX

XXXXXXXX XXXXX (XXX XXXXXXX X MIMO XXXXXX)

Xxxxxxxx xxxxx xx xxxxxxx X4.1 x X4.2 jsou Xxxxxxxxxx xxxxx.

Xxxxx zařazené xx xxxx X4.3 x X4.4 xxxx Xxxxxxxxxxxx xxxxx.

Xxxxxxxxxxx xxxxxxxxx x xxxxxxxxxxx xxxxxxxxxx jsou xxxxxxxx.

X4.1. XXXXXXXXXX XXXXXXXX

Xxxx xxxx xxxxxx:

2-xxxxxxxxxxx (5ɑ-xxxxxxx-2-xx-17-xx)

xxxxxxxx-1,4,6-xxxxx-3,17-xxxx (xxxxxxxxxxxxxxxxx)

2-xxxxxxxxxxx (5ɑ-xxxxxxx-2-xx-17-xx)

xxxxxxxx-3,5-xxxx-7,17-xxxx (xxxxxxxxx)

3-xxxxxxxxxxx (5ɑ-xxxxxxx-3-xx-17-xx)

xxxxxxxxx

3-xxxxxxxxxxx (5ɑ-xxxxxxx-3-xx-17-xx)

xxxxxxxxx

4-xxxxxxxxx-3,6,17 xxxxx (6-xxx)

xxxxxxxx

xxxxxxxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxxx

X4.2. XXXXXXXXXXXXXX XXXXX [XXXXXXXXXXXXX A XXXXXXXXXX XXXXXXXXXX ESTROGENOVÝCH XXXXXXXXX (XXXXX)]

Xxxx jiné včetně:

arformoterol

indakaterol

reproterol

tretoquinol (xxxxxxxxxxxxx)

xxxxxxxxx

xxxxxxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxx

xxxxxxxxx

xxxxxxxxxx

xxxxxxxxxx

X4.3. LÁTKY ZABRAŇUJÍCÍ XXXXXXXX XXXXXXXXX XXXXXXXX XXX

Xxxx xxxx xxxxxx:

xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxx X

xxxxxxxxxx xxxxxxxxxx, xxxx.:

xxxxxxxxxx xxxxxxxxx xxxxxxxx XXX, xxxx.:

- xxxxx xxxxxxxxx xxxx xxxxxx expresi xxxxxxxxxx

- xxxxxxx xxxxxxxxx aktivinu (xxxx. XXX-031)

- proteiny xxxxxx myostatin (např. xxxxxxxxxxx, propeptid xxxxxxxxxx)

xxxxxxxxxx xxxxx receptoru xxxxxxxx XXX (xxxx. xxxxxxxxxx)

- xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx xxxx xxxxxxxxxx (xxxx. xxxxxxxxxxx, domagro xxxxx, xxxxxxxxxxxxx, xxxxxxxxxx)

X4.4. XXXXXXXXXXX XXXXXXXXXX

X4.4.1 aktivátory AMP-aktivované xxxxxxxxxxxxx (XXXX), xxxx. XXXXX, agonisté peroxizomovými xxxxxxxxxxx xxxxxxxxxxxx receptoru xxxxx (XXXXδ), xxxx. 2-(2-xxxxx-4-((4-xxxxx-2-(4- (trifluormetyl)fenyl)thiazol-5-yl)metylthio)fenoxy) xxxxxxxx xxxxxx (XX1516, GW501516) x xxxxxxxx Rev-erbɑ , xxxx. SR9009, XX9011

X4.4.2 insuliny x xxxxxxxx xxxxxxxx

X4.4.3 meldonium

S4.4.4 xxxxxxxxxxxx

X5 XXXXXXXXX X XXXXXXXXX XXXXX

XXXXXXXX XXXXX (XXX SOUTĚŽI X XXXX XXXXXX)

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.

Xxxxxxx xxxxxxxxx a xxxxxxxxx xxxxx, xxxxxx xxxxx xxxxxxxxx izomerů, xxxx. x- x x-, xxxx xxxxxxxx.

Xxxx xxxx xxxxxx:

•&xxxx; Xxxxxxxxx, xxxx např.:

acetazolamid; xxxxxxxx; xxxxxxxxx; kanrenon; xxxxxxxxxxxx; xxxxxxxx etakrynová; xxxxxxxxx; xxxxxxxxx; xxxxxxxxx; spironolakton; xxxxxxxx, xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx x xxxxxxxxxxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx;

• Vaptany, xxxx. konivaptan, xxxxxxxxxx, xxxxxxxxx;

• Xxxxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxxxxxxx, např.:

albumin, xxxxxxx, xxxxxxxxxxx xxxxx, xxxxxxxx;

• Desmopresin;

• Xxxxxxxxxx;

x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými biologickými xxxxxx.

XXXXXXX

• drospirenon; pamabrom; x lokální oftalmologické xxxxxxxx xxxxxxxxxx karboanhydrázy (xxxx. xxxxxxxxxx, xxxxxxxxxxx);

• xxxxxxx xxxxxx xxxxxxxxxxx x xxxxx anestezii.

POZNÁMKA

Nález xxxxxxxxxxx xxxxxxxx látky xx xxxxxxxxxx xxxxxxxx xxxxxxx: x formoterolu, xxxxxxxxxxx, xxxxxx, xxxxxxxx, xxxxxxxxxxxxx x xxxxxxxxxxxxxx xx Xxxxxx Xxxxxxxxx xxxxxxxx nebo xxxxxxxx Xxx Xxxxxxx ve xxxxxxx s xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxxx (xxxxx xxxxxxxxx xxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxx lokálního xxxxxx xxxxxxxxxxx x xxxxxxxx xxxxxxxxx), xxxx xxxxxxxxx za Xxxxxxxxx xxxxxxxxxxx nález (AAF), xxxxx Xxxxxxxxx nemá xxxxxxxxxx Terapeutickou výjimku (XX) na xxxx xxxxx navíc x xx, xxxxx xxx xxxx xxxxxxx na xxxxxxxxxx nebo jinou xxxxxxxxx xxxxx.

XXXXXXXX XXXXXX

XXXXXXXX XXXXX (XXX XXXXXXX X XXXX XXXXXX)

Xxxxxxx xxxxxxxx xxxxxx x xxxx xxxxx xxxx Xxxxxxxxxxxx x xxxxxxxx xxxxx x M2.2, xxx jsou Xxxxxxxxxx xxxxxx.

X1. XXXXXXXXXX S XXXX A XXXXXXXX XXXXXXXXXXXX

Xxxxxxxx je xxxxxxxxxxx:

X1.1. Xxxxxx xxxx opětovné xxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxx, allogenní (xxxxxxxxx) xxxx xxxxxxxxxxx krve xxxx xxxxxxxx z xxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxxx xxxxxxx s xxxxxxxx xxxxxxxx xxxxxx xxxx xxxxxx xxxxxx Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxxx provedené x xxxxxxxxxxxxx xxxxxxxxx xxxxxx.

X1.2. Xxxxx xxxxxxxxx xxxxxx, xxxxxxx xxxx xxxxxxx xxxxxxx.

Xxxx jiné xxxxxx:

Xxxxxxxxxxxxxxxxxxx; xxxxxxxxxxx (RSR13); xxxxxxxxx x modifikované xxxxxxxxxxxxx xxxxxxxx, např. xxxxxx xxxxxxxx na xxxx xxxxxxxxxxx x xxxxxxxxxxxxxxxx xxxxxxxxxxxxx produkty, x xxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxxx.

X1.3. Xxxxxxxxx xxxxx xxxxxxxxxxxxxxx xxxxxxxxxx x krví nebo x xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxxxx xxxxxxx.

X2. CHEMICKÁ X XXXXXXXXX XXXXXXXXXX

Xxxxxxxx je xxxxxxxxxxx:

X2.1. Xxxxxxxxx xxxx Xxxxx x xxxxxx xx xxxxxx porušit xxxxxxxxx x xxxxxxxx Xxxxxx xxxxxxxxxx xxx Xxxxxxxxx xxxxxxxx.

Xxxx xxxx xxxxxx:

Xxxxxx a/nebo xxxxxx Xxxxxx, např. přidáním xxxxxxx ke Xxxxxx.

X2.2. Xxxxxxxxxx infuze a/nebo xxxxxxx xxxx xxx xxxxxx 100 xx xx 12 xxxxx xxxxx infuzí xxxxxxxxx xxxxxxxxx x xxxxxxx xxxxxxxxxxxx xxxxxxxx, xxxxxxxxxxxxx xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx.

X3. XXXXXX X BUNĚČNÝ XXXXXX

X xxxxxx xxxxxxxxxxxxxxx zvýšení xxxxxxxxxxx výkonu xx xxxxxxxx xxxxxxxxxxx:

X3.1. Xxxxxxx xxxxxxxxxx kyselin xxxx xxxxxx xxxxxxx, xxxxx xxxxx změnit xxxxxxxx xxxxxx a/nebo xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxx. Xx mimo jiné xxxxxxxx xxxxxxxxxxx xxxxx xxxx, xxxxxxxxx genů x technologie xxxxxxx xxxx.

X3.2. Použití normálních xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxx.

X6 STIMULANCIA

ZAKÁZANÉ PŘI XXXXXXX

Xxxxxxx xxxxxxxx látky x této xxxxx xxxx Xxxxxxxxxx xxxxx x xxxxxxxx xxxxx xxxxxxxxx v X6.X, xxx xxxx Xxxxxxxxxxxx xxxxx.

Xxxxxxxx xxxxx x xxxx xxxxx: xxxxxx x metylendioxymetamfetamin (XXXX/„xxxxxx“)

Xxxxxxx xxxxxxxxxxx, xxxxxx všech xxxxxxxxx xxxxxxx, xxxx. x- x x-, xxxx xxxxxxxx.

Xxxxxxxxxxx xxxxxxxx:

X6.X: XXXXXXXXXXXX STIMULANCIA

adrafinil

fonturacetam [4-xxxxxxxxxxxxxx (xxxxxxxx)]

xxxxxxxxxx

xxxxxxxxxx

xxxxxxxxx

xxxxxxxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxx

xxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxxx

xxxxxxxx

xxxxxxxxxxxxxxx

xxxxxxxxxxxx(x-)

xxxxxxxxx

x-xxxxxxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxx

xxxxxx

xxxxxxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxxxxxx

xxxxxxxxxx

xxxxxxxxx

xxxxxxxx

xxxxxxxxxx

xxxxxxxxx

xxxxxxxxx

xxxxxxxxxxx

xxxxxxxxxxx

Xxxxxxxxx, xxxxx xxxx xxxxxxxx xxxxxx x xxxxx xxxxxx, xx Xxxxxxxxxxx látkou.

S6.B: XXXXXXXXXX XXXXXXXXXXX

Xxxx jiné xxxxxx:

2-xxxxxxxxxxx-1-xxxx (ß-xxxxxxxxxxxxxx-xxxx, XXXXX)

xxxxxxxxxxx

xxxxxxxxx

3-xxxxxxxxxx-2-xxxx (1,2-xxxxxxxxxxxxxxxxx)

xxxxxxxxxxx

xxxxxxxxx (xxxxxxxxxxxxx)

4-xxxxxxxxxxxxxxxxxx

xxxxxxxxxxx

xxxxxxx

4-xxxxxxxxxx-2-xxxx (1,3-dimetylamylamin, 1,3 XXXX, xxxxxxxxxxxxxx)

xxxxxxxxxx

xxxxxxxxxxx

4-xxxxxxxxxxxx-2-xxxx (1,3-xxxxxxxxxxxxxxxxx)

xxxxxxxxxx (xxxxxxxxx)

xxxxxxxxxxx x xxxx xxxxxxxx

5-xxxxxxxxxx-2-xxxx (1,4-xxxxxxxxxxxxxxx, 1,4-xxxxxxxxxxxxxxxxx, 1,4-XXXX)

xxxxxxxxxxxxxxxx (parahydroxyamfetamin)

fenmetrazin

benzfetamin

isomethepten

fenprometamin

katin1)

levmetamfetamin

propylhexedrin

katinon x xxxx xxxxxxx, xxxx. xxxxxxxx, metedron a ɑ-xxxxxxxxxxxxxxxxxxxxxx

xxxxxxxxxxxx

xxxxxxxxxxxxx2)

xxxxxxxxxxxxxx (xxxxxxxxxxxxxxxx)

xxxxxxxxxxxxxxxxxxxxxxxx

xxxxxxxxx

xxxxxxx3)

xxxxxxxxxxxx3)

xxxxxxxxxx

xxxxxxxxx (xxxxxxxxx)4)

xxxxxxxxxxxxx [(±)-xxxxx-2-(xxxxxxxx-2-xx)-2-(xxxxxxxxx-2- yl)acetát]

solriamfetol

etamivan

metylfenidát

strychnin

etylfenidát

niketamid

tenamfetamin (xxxxxxxxxxxxxxxxxxxxx)

xxxxxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxxxxxx

xxxxxxxxx

xxxxxxxx (1,5-xxxxxxxxxxxxxxxx)

x další látky x xxxxxxxx chemickou xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx

XXXXXXX

• xxxxxxxx;

• xxxxxxxx xxxxxxxxxxx x xxxxxxx jejich xxxxxxx, xxxxxxx, xxxxxx nebo xxxxxx použití (xxxx. xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, nafazolin, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxx) x stimulancia zařazená xx Xxxxxxxxxxxxxx xxxxxxxx 20245).

X7 XXXXXXXXX

XXXXXXXX PŘI XXXXXXX

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Specifické látky.

Návykové xxxxx x xxxx xxxxx: xxxxxxxxx (xxxxxx)

Xxxxxxxxxxx xxxxxxxxx, xxxxxx xxxxxx xxxxxxxxxx xxxxx xxxxxxxxx xxxxxxx, xxxx. x- x x, xxxx xxxxxxxx.

xxxxxxxxxxx

xxxxxxxx x jeho xxxxxxxx

xxxxxx

xxxxxxxxxx

xxxxxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxxx

xxxxxxx

xxxxxxxxx (heroin)

metadon

oxykodon

tramadol

oxymorfon

S8 XXXXXXXXXXX

XXXXXXXX XXX XXXXXXX

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Specifické xxxxx. Návykové xxxxx x této xxxxx: xxxxxxxxxxxxxxxxxxx (XXX)

Xxxxxxx xxxxxxxx x xxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxx, např.

• x xxxxxx (xxxxx, xxxxxxxxx) x konopných xxxxxxxxxx

• xxxxxxxx a xxxxxxxxxx xxxxxxxxxxxxxxxxxxxxx (XXX)

• xxxxxxxxxx kanabinoidy napodobující xxxxxx XXX

XXXXXXX

• kanabidiol

S9 XXXXXXXXXXXXXXX

XXXXXXXX XXX SOUTĚŽI

Všechny xxxxxxxx xxxxx x xxxx xxxxx jsou Xxxxxxxxxx xxxxx.

Xxxxxxx glukokortikoidy xxxx xxxxxxxx, xxxxx xxxx podávány xxxxxxxxxx xxxxxxxx, xxxxxxxxx [včetně xxxxxxxxxx (např. xxxxxxx, xxxxxxxxxx, xxxxxxxxxxxx)] xxxx xxxxxxxx xxxxxx.

Xxxx xxxx xxxxxx:

xxxxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxx

xxxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxx

xxxxxxxxxxxx

xxxxxxxxx

xxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxxxx xxxxxxxx

xxxxxxxx

xxxxxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxxxxxxxxx

XXXXXXXX

• Xxxx xxxxxxx podání (xxxxxx xxxxxxxxxxx x xxxxxxxxx: xxxxxxxx-xxxxxxxxxxxxxx, xxxxxxxxxx, intranazálního, xxxxxxxxxxxxxxxx, xxxxxx x xxxxxxxxxxxx) nejsou xxxxxxxx, xxxxx xx používají x xxxxx xxxxxxxx xxxxxxxxxxxx xxxxx x xxxxxxxxxxxxxx indikací.

P1 XXXX-XXXXXXXXX

XXXXXXXX X URČITÝCH SPORTECH

Všechny xxxxxxxx xxxxx x xxxx xxxxx jsou Xxxxxxxxxx xxxxx.

Xxxx-xxxxxxxxx xxxx xxxxxxxx xxxxx x xxxxxxxxxxxxx xxxxxxxx Xxx Xxxxxxx a xxx xx to xxxxxxxx xxxxxxxx (*) x Xxxx soutěž.

• xxxxxxxxxxx (XX)*

• xxxxxxxx/xxxxxxxxxxxx (XXX) – xxxxx xx xxxxxx, akrobatické skoky / U-rampa a xxxxxxxxx U-rampa / xxx air

• xxxxxxxxxxxx xxxxx (XXX)

• podvodní xxxxxx (XXXX)* x xxxxxxxxxxxx xxxxxxx xxxxxxxx, xxxx harpunou x xxxxxxx na xxxx

• xxxxxxxx (všechny disciplíny) (XXXX)

• šipky (XXX)

• xxxx (XXX)

• xxxxxxxx (XXX)

• xxxxxxx (XXXX, XXX)*

* xxxxxxxx xxxx Xxxx xxxxxx

Xxxx xxxx xxxxxx:

xxxxxxxxxx

xxxxxxx

xxxxxxxxx

xxxxxxxxxx

xxxxxxxxxx

xxxxxxxxx

xxxxxxxxxxxx

xxxxxxxx

xxxxxxxx

xxxxxxxxxx

xxxxxxxxxx

xxxxxxxxxxx

xxxxxxxxx

xxxxxxxxxx

xxxxxxx

xxxxxxx

xxxxxxxxxx

xxxxxxx

xxxxxxxxx

xxxxxxx

Xxxxxxx x. 2

Xxxxx xxxxxxxxxxx smlouvy x xxxxxxxxx xxxxxx
&xxxx;

1) xxxxx (x-xxxxxxxxxxxxxxxx) a xxxx x-xxxxxx: xx zakázaný xxxxx xxx koncentraci x xxxx vyšší xxx 5 xxxxxxxxxx x 1 ml.

2) xxxxxxxxxxxxx: zakázaný pouze xxx koncentraci x xxxx xxxxx xxx 150 mikrogramů x 1 xx.

3) xxxxxxx x xxxxxxxxxxxx: xxxxxxxx xxx koncentraci x xxxx xxxxx xxx 10 mikrogramů v 1 xx.

4) epinefrin (xxxxxxxxx): xxxx zakázáno xxxxxxx xxxxxxxx, xxxx. xxxxx, xxxx, xxxx xxxxxxxx podávání x xxxxxxxxx anestetiky.

5) xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, xxxxxxxxx a xxxxxxxx: xxxx xxxxx xxxx xxxxxxxx xx Xxxxxxxxxxxxxx xxxxxxxx 2024 x nejsou považovány xx Xxxxxxxx xxxxx.

Informace

Právní xxxxxxx x. 19/2025 Xx. xxxxx xxxxxxxxx xxxx 28.1.2024.

Xxxxx xxxxxxxxxxxx xxxxxxxx xxxxx xxxxxx xxxxxxxx xxxxxxxx x xxxxxxxx xxxx xxxxxxxxxxxxx, xxxxx xx xxxx xxxxxx xxxxxxxxx xxxxx shora xxxxxxxxx xxxxxxxx xxxxxxxx